{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-25-000107","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.488209+00:00","generated_at":"2026-05-17T11:56:03.734139+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Salarius Pharma CEO David J. Arthur resigns; CFO Mark J. Rosenblum named acting CEO","bullets":["David J. Arthur resigned as CEO effective Aug 17, 2025; not due to any disagreement with the company.","Mark J. Rosenblum appointed acting CEO, continuing as EVP and CFO; no new employment agreement.","Consulting agreement with Arthur terminated immediately upon resignation.","Rosenblum has served as EVP Finance/CFO since Sep 2019; previously CFO of Advaxis, Inc.","Company working to finalize previously announced merger with Decoy Therapeutics Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-25-000107","json":"https://secwatch.observer/filing/0001615219-25-000107.json","markdown":"https://secwatch.observer/filing/0001615219-25-000107.md","text":"https://secwatch.observer/filing/0001615219-25-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000107/0001615219-25-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000107/flks-20250817.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:56:03.734139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}